cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Blueprint Medicines Corp
9 own
5 watching
Current Price
$86.09
$0.91
(1.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,420.17M
52-Week High
52-Week High
101.00000
52-Week Low
52-Week Low
43.89000
Average Volume
Average Volume
0.39M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
17.8934
iconMarket Capitalization3,420.17M
icon52-Week High101.00000
icon52-Week Low43.89000
iconAverage Volume0.39M
iconDividend Yield--
iconP/E Ratio17.8934
What does the Blueprint Medicines Corp do?
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Blueprint Medicines Corp make?
News & Events about Blueprint Medicines Corp.
PR Newswire
11 months ago
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass., April 26, 2023 CAMBRIDGE, Mass...
Benzinga
1 year ago
Latest Ratings for BPMC DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform View More Analyst Ratings for BPMC View the Latest Analyst Ratings read more...
Ticker Report
1 year ago
Needham Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC Get Rating) in a research report report published on Friday, Benzinga reports. They currently have a $60.00 price target on the biotechnology companys stock. Other analysts have also ...
Zolmax
1 year ago
Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) has been given a consensus recommendation of Moderate Buy by the nineteen analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold ...
Frequently Asked Questions
Frequently Asked Questions
What is Blueprint Medicines Corp share price today?
plus_minus_icon
Can Indians buy Blueprint Medicines Corp shares?
plus_minus_icon
How can I buy Blueprint Medicines Corp shares from India?
plus_minus_icon
Can Fractional shares of Blueprint Medicines Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Blueprint Medicines Corp stocks?
plus_minus_icon
What is today’s traded volume of Blueprint Medicines Corp?
plus_minus_icon
What is today’s market capitalisation of Blueprint Medicines Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Blueprint Medicines Corp?
plus_minus_icon
What percentage is Blueprint Medicines Corp down from its 52-Week High?
plus_minus_icon
What percentage is Blueprint Medicines Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$86.09
$0.91
(1.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00